Abstract: It is an object of the present invention to provide antibodies capable of detecting an active TGF-? generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-?) generated as a result of generation of active form of human TGF-?1, human TGF-?2 and human TGF-?3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-?1, and corresponding regions of human TGF-?2 and human TGF-?3.

Abstract: It is an object of the present invention to provide antibodies capable of detecting an active TGF-? generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-?) generated as a result of generation of active form of human TGF-?1, human TGF-?2 and human TGF-?3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-?1, and corresponding regions of human TGF-?2 and human TGF-?3.

Abstract: Provided is a novel mucin-type glycoprotein and a method for producing the same. Specifically, a mucin-type glycoprotein having a repeat structure including 3 to 2000 repeating units each having an amino acid sequence represented by the formula I: Val-Xaa-Glu-Thr-Thr-Ala-Ala-Pro [wherein Xaa represents Val or Ile] (SEQ ID NO: 1), wherein one or more amino acid residues in the structure are bound to a sugar chain of one or more monosaccharides. Also provided is a composition containing the novel mucin-type glycoprotein. Further provided is a molecular weight marker containing the novel mucin-type glycoprotein.

Abstract: It is an object of the present invention to provide antibodies capable of detecting an active TGF-? generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-?) generated as a result of generation of active form of human TGF-?1, human TGOF-?2 and human TGF-?3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-?1, and corresponding regions of human TGF-?2 and human TGF-?3.

Abstract: Provided is a novel mucin-type glycoprotein and a method for producing the same. Specifically, a mucin-type glycoprotein having a repeat structure including 3 to 2000 repeating units each having an amino acid sequence represented by the formula I: Val-Xaa-Glu-Thr-Thr-Ala-Ala-Pro [wherein Xaa represents Val or Ile] (SEQ ID NO: 1), wherein one or more amino acid residues in the structure are bound to a sugar chain of one or more monosaccharides. Also provided is a composition containing the novel mucin-type glycoprotein. Further provided is a molecular weight marker containing the novel mucin-type glycoprotein.

Abstract: A system completely automates process steps to reduce contamination, enables quantification of products, and reduces the defective ratio. Sample containers are transported on a unit by unit basis, each unit consisting of a predetermined number of containers, and supplied to the individual dispensing/aspiration apparatuses and each reaction bath. In order to ensure quantification and reliability of the reaction/processing of the sample, a reaction monitoring sensor is provided, and the sample containers are affixed with barcodes to identify the samples. Samples determined through monitoring to be defective are returned to a predetermined step site where reaction/processing is performed again.

Abstract: It is an object of the present invention to provide antibodies capable of detecting an active TGF-? generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-?) generated as a result of generation of active form of human TGF-?1, human TGOF-?2 and human TGF-?3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-?1, and corresponding regions of human TGF-?2 and human TGF-?3.

Abstract: The present inventors isolated and purified elicitor-binding proteins in good yield by combining the development of a column that uses APEA derivatives, pre-columns to remove non-specifically adsorbing substances, and effective elution methods. Using the N-terminal and internal chain amino acid sequences of the obtained proteins, the present inventors successfully isolated cDNAs encoding the proteins of the present invention from a rice cDNA library. Moreover, when anti-Con A-CEBiP antibodies were purified and their effect on elicitor-responsive reactive oxygen production was examined, production of reactive oxygen was inhibited by a pretreatment with the antibodies, suggesting that the present proteins are receptor proteins involved in chitin oligosaccharide elicitor responses. Since these elicitors induce resistance to blast in rice, the proteins of the present invention can be applied to the development of novel disease control technologies.

Abstract: A purpose of the present invention is to clarify the mechanism of the intrinsic clotting system which is induced by activation of blood coagulation factor IX by erythrocyte membrane, and to clarify the structure of a factor which activates blood coagulation factor IX by isolating and identifying the factor.

Abstract: A purpose of the present invention is to clarify the mechanism of the intrinsic clotting system which is induced by activation of blood coagulation factor IX by erythrocyte membrane, and to clarify the structure of a factor which activates blood coagulation factor IX by isolating and identifying the factor.